- New FDA Warning on Cetirizine and Levocetirizine
- New FDA Warning for Extended-Release Stimulants for ADHD
- No Added Benefit from Concomitant Use of GLP-1 RAs or Dual GIP/GLP-1 RAs with DPP-4 Inhibitors
- Pharmacologic Approaches to Glycemic Treatment for Adults with Type 2 Diabetes
- Incoming Members of the DUR Commission
- Opioid Prescribing for Acute Pain Management in Children and Adolescents in Outpatient Settings
- Outgoing Member of the DUR Commission
- FDA Updates to Prescribing Information for Opioids
- Outgoing Member of the DUR Commission
- New State Pharmacy Consultant
- DUR Public Comment
- DUR Activities
- New GOLD Strategy for Initial COPD Pharmacologic Management
- Naloxone
- DUR Public Comment
- DUR Activities
- Benzodiazepine ProDUR Edits - Coming Soon
- Outgoing Members of the DUR Commission
- Incoming Members of the DUR Commission
- DUR Public Comment